TPM4 新型无义变异导致显性巨大血小板减少症、轻度出血倾向及细胞骨架重塑障碍
研究在一个遗传性血小板疾病西班牙多中心项目中,对因终生血小板减少和出血入组的先证者家系进行临床与实验室表型分析及全外显子测序,发现 TPM4 新型无义变异 c.322C>T(p.Gln108*)与巨大血小板减少症共分离,患者血小板聚集和颗粒分泌正常,但铺展能力受损、TPM4 定位异常且蛋白水平显著降低,TPM2 和 TPM3 mRNA 上调。
要点
- TPM4 无义变异 c.322C>T(p.Gln108*)与巨大血小板减少症共分离。
- 患者血小板对多种激动剂的聚集和颗粒分泌反应正常。
- 变异导致血小板铺展能力受损及 TPM4 蛋白水平显著降低。
核心结论
- 本研究鉴定出一个与巨大血小板减少症共分离的新型 TPM4 无义变异,并发现血小板细胞骨架重塑和铺展受损。
- 这些发现支持 TPM4 在血小板生成中的重要作用,并扩展了对 TPM4 相关血小板减少症的认识。
研究设计与样本
- 先证者因终生血小板减少和出血入组西班牙遗传性血小板疾病多中心项目。
- 采用 ISTH-BAT 记录出血评分,实验室表型分析包括血细胞计数、血涂片、血小板聚集和流式细胞术分析。
- 通过全外显子测序(WES)进行基因分型,并用免疫荧光和免疫印迹分析静息/铺展血小板的细胞骨架蛋白。
主要发现
- 5 名家庭成员表现为终生轻度血小板减少,血涂片中大量血小板增大,并有轻度出血倾向。
- 患者血小板对多种激动剂的聚集和颗粒分泌反应正常。
- WES 发现 TPM4(NM_003290.3)新型无义变异 c.322C>T(p.Gln108*)。
- 该变异导致 TRAP-6 和 CRP 刺激后血小板铺展能力受损、活化血小板中 TPM4 定位异常,以及血小板裂解物中 TPM4 水平显著降低。
- 先证者 TPM2 和 TPM3 mRNA 水平上调。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rare inherited thrombocytopenias are caused by alterations in genes involved in megakaryopoiesis, thrombopoiesis and/or platelet release. Diagnosis is challenging due to poor specificity of platelet laboratory assays, large numbers of culprit genes, and difficult assessment of the pathogenicity of novel variants. OBJECTIVES: To characterize the clinical and laboratory phenotype, and identifying the underlying molecular alteration, in a pedigree with thrombocytopenia of uncertain etiology. PATIENTS/METHODS: Index case was enrolled in our Spanish multicentric project of inherited platelet disorders due to lifelong thrombocytopenia and bleeding. Bleeding score was recorded by ISTH-BAT. Laboratory phenotyping consisted of blood cells count, blood film, platelet aggregation and flow cytometric analysis. Genotyping was made by whole-exome sequencing (WES). Cytoskeleton proteins were analyzed in resting/spreading platelets by immunofluorescence and immunoblotting. RESULTS: Five family members displayed lifelong mild thrombocytopenia with a high number of enlarged platelets in blood film, and mild bleeding tendency. Patient's platelets showed normal aggregation and granule secretion response to several agonists. WES revealed a novel nonsense variant (c.322C>T; p.Gln108*) in TPM4 (NM_003290.3), the gene encoding for tropomyosin-4 (TPM4). This variant led to impairment of platelet spreading capacity after stimulation with TRAP-6 and CRP, delocalization of TPM4 in activated platelets, and significantly reduced TPM4 levels in platelet lysates. Moreover, the index case displayed up-regulation of TPM2 and TPM3 mRNA levels. CONCLUSIONS: This study identifies a novel TPM4 nonsense variant segregating with macrothrombocytopenia and impaired platelet cytoskeletal remodeling and spreading. These findings support the relevant role of TPM4 in thrombopoiesis and further expand our knowledge of TPM4-related thrombocytopenia.
引用
- Marín-Quílez A, Vuelta E, Díaz-Ajenjo L, et al. A novel nonsense variant in TPM4 caused dominant macrothrombocytopenia, mild bleeding tendency and disrupted cytoskeleton remodeling. J Thromb Haemost. 2022. PMID: 35170221. doi:10.1111/jth.15672
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。